Beijing Wandong Kangyuan Technology Development Co.,Ltd was established in July 2000. It is a Sino-foreign joint venture with equity participation by Beijing Wandong Medical Technology Co., Ltd. (an A-share listed company). The company is committed to the research and development, manufacturing, commercial marketing and after-sales service of new products in the field of blood health products.It is a fully integrated high-tech Class III medical device enterprise covering the entire industry chain of science, industry and trade.
The company is located in Yizhuang New Town, Beijing, within the Beijing Economic-Technological Development Area. It is certified as a National High-Tech Enterprise,a Beijing "Specialized, Refined, Distinctive, and Innovative"Small and Medium sized Enterprise Certificate,a Zhongguancun High-Tech Enterprise in Beijing,and a Beijing Innovative Small and Medium sized Enterprise.
The company has a backbone R&D team composed of clinical experts and industry senior engineers with intermediate and senior professional titles. For years, the company has consistently prioritized technological leadership, continuously innovating and developing in the field of blood health products, and has obtained multiple invention patents and utility model patents.
The company's factory covers an area of nearly 4,000 square meters, featuring a Class 10,000 biological laboratory and a Class 100 biological testing platform. With over 1,000 square meters of Class 100,000 cleanrooms, the company has passed the GMP on-site inspection by the China Food and Drug Administration, and has obtained both ISO 9001 Quality Management System Certification and ISO 13485 Medical Device Quality Management System Certification. It is one of the few medical device enterprises in China that possesses large-scale production capabilities for both active medical devices and passive medical devices.
After over 20 years of exploration and expansion, the company has established and developed a mature nationwide commercial sales network for its blood health product series. The company's core products, the BW Series Autologous Blood Recovery Systems BW-8100A, BW-8200A/BW-8200B and disposable blood recovery consumables, have been clinically applied in more than 1,000 hospitals at all levels (including hundreds of tertiary hospitals) in 32 provinces (municipalities, autonomous regions) across the country, achieving good social and economic benefits.
over 20 years of Development
Products cover more than 30 provinces
Over 1000 hospitals at all levels
The autologous blood recovery system collects blood lost during or after surgery, anticoagulates it, and stores it in a sterilized blood reservoir. Through processes including filtration, centrifugation, and washing, it removes cellular debris, activated clotting factors, free hemoglobin, and anticoagulants. The intact red blood cells are then transferred to a blood bag for storage, ready for reinfusion into the patient.
These systems are widely used in surgical procedures with anticipated blood loss exceeding 20% of total volume requiring standard blood cross-matching, including but not limited to: Trauma surgery, traumatic injuries, and combat-related hemorrhages, such as liver/spleen rupture, spinal trauma, and massive hemorrhage resuscitation; Cardiovascular surgeries; Organ transplantation (heart, liver, and kidney transplants);Orthopedic procedures: total hip replacements and spinal surgeries; Obstetrics/gynecology: ruptured ectopic pregnancy with massive hemorrhage ;Abdominal surgeries: hepatic/splenic procedures and portal hypertension shunt operations; Urologic major hemorrhage surgeries ; Neurosurgical procedures.
Autologous blood recovery systems can recover over 90% of lost blood, conserving precious blood resources. They not only alleviate blood supply shortages, but also prevent adverse reactions associated with allogeneic blood transfusions and potential transmission of blood-borne infectious diseases.
This technology represents a breakthrough in medical science, transforming traditional transfusion concepts and methodologies. It has made "saving oneself with one's own blood" a clinical reality, standing as a milestone in the advancement of transfusion medicine.Particularly for China - a nation with 1.3 billion population, chronic blood supply shortages, and high incidence rates of infectious diseases like hepatitis, the widespread adoption of autologous blood recovery technology carries tremendous social significance and economic benefits, playing a vital role in enhancing public health standards.
